Phase 1 Trial BL0020 Toripalimab Recurrent Small Cell Lung Cancer
ClinicalTrials.gov Studies
Summary
A Phase 1 clinical trial evaluating BL0020 Injection combined with Toripalimab Injection is registered for patients with recurrent extensive-stage small cell lung cancer (ES-SCLC). The trial, designated NCT07550842 and registered April 24, 2026, targets a disease that accounts for approximately 14% of all newly diagnosed lung cancers and has poor survival outcomes. ES-SCLC represents approximately 70% of SCLC cases at diagnosis and is currently treated with immune checkpoint inhibitors combined with platinum-based systemic therapy.
“Small cell lung cancer (SCLC) is a highly heterogeneous and aggressive disease with poor survival outcomes.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A Phase 1 clinical trial (NCT07550842) is registered to evaluate the safety and efficacy of BL0020 Injection in combination with Toripalimab Injection for patients with recurrent extensive-stage small cell lung cancer. The trial focuses on an aggressive disease that accounts for approximately 14% of all lung cancer diagnoses and carries poor prognosis, with the majority of patients diagnosed at the extensive stage. Healthcare providers and clinical investigators conducting oncology research may find this trial relevant for understanding emerging combination therapies for ES-SCLC.
Patients with recurrent extensive-stage small cell lung cancer represent the affected population. The trial investigates a combination of BL0020 and toripalimab, an immune checkpoint inhibitor, as a potential treatment approach for a disease with limited long-term survival options under current standard of care.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Phase 1 NCT07550842 Kind: PHASE1 Apr 24, 2026
Abstract
Lung cancer remains the leading cause of cancer deaths worldwide; in 2022, there were approximately 2.48 million new cases and 1.8 million deaths from lung cancer globally. Globally, lung cancer is the leading cause of cancer-related deaths in men and the second leading cause in women after breast cancer. Among them, small cell lung cancer (SCLC) accounts for approximately 14% of all newly diagnosed lung cancers. Small cell lung cancer (SCLC) is a highly heterogeneous and aggressive disease with poor survival outcomes.
A 2-stage system dividing patients into limited and extensive disease was developed in 1973 by the United States (US) Veteran's Administration Lung Cancer Study Group (VALG), which has been used to this day. Patients with limited-stage SCLC can be treated with chemotherapy and radiation with the potential for long-term survival. However, the majority (approximately 70%) of patients with SCLC are diagnosed with extensive-stage SCLC (ES-SCLC), which has poor survival prospects. Chest pain, dyspnea, and cough are among the most frequent disease-related symptoms experienced by patients with SCLC. Immune checkpoint inhibitors in combination with platinum-based systemic therapy can palliate symptoms and prolong survival for patients with ES-SCLC. However, long-term survival is rare.
The current standard first-line treatment for patients with ES-SCLC is immune checkpoint inhibitors in combination with platinum-based systemic therapy. Despite the impressive high o...
Conditions: Small Cell Carcinoma of Lung
Interventions: BL0020, Toripalimab
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.